Detalhe da pesquisa
1.
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
Lancet
; 401(10387): 1518-1529, 2023 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062298
2.
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Pediatr Dermatol
; 40(6): 1003-1009, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37455588
3.
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Mod Rheumatol
; 29(5): 756-766, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30489177
4.
Tofacitinib versus methotrexate in rheumatoid arthritis.
N Engl J Med
; 370(25): 2377-86, 2014 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-24941177
5.
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Rheumatology (Oxford)
; 55(6): 1031-41, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26929445
6.
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Clin Exp Rheumatol
; 34(3): 430-42, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27156561
7.
Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.
BMC Musculoskelet Disord
; 17(1): 348, 2016 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27538585
8.
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
N Engl J Med
; 367(6): 495-507, 2012 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22873530
9.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
N Engl J Med
; 367(6): 508-19, 2012 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22873531
10.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Lancet
; 381(9865): 451-60, 2013 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23294500
11.
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Ann Rheum Dis
; 73(1): 124-31, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23482473
12.
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
Arthritis Rheum
; 65(3): 559-70, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23348607
13.
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Ann Intern Med
; 159(4): 253-61, 2013 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24026258
14.
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995-2016.
Dermatol Ther (Heidelb)
; 14(4): 993-1006, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38625633
15.
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
J Clin Pharmacol
; 64(1): 67-79, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37691236
16.
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
Am J Clin Dermatol
; 25(2): 299-314, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263353
17.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Arthritis Rheum
; 64(4): 970-81, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22006202
18.
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Arthritis Rheum
; 64(3): 617-29, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21952978
19.
Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database.
J Dermatol
; 50(9): 1121-1128, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37291688
20.
Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database.
Dermatol Ther (Heidelb)
; 13(8): 1733-1746, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296372